LIVE 12:30 pm – 1:30 pm 4/26/2016 Fireside Chats: Andy Slavitt, Acting Administrator, CMS & Giovanni Caforio, MD, CEO, Bristol-Myers Squibb @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston
2016 World Medical Innovation Forum: CANCER, April 25-27, 2016,
Partners HealthCare, Boston, at the Westin Hotel, Boston
ANNOUNCEMENT
Leaders in Pharmaceutical Business intelligence (LPBI) Group
Streaming in Real Time using Social Media this Event on
CANCER Innovations
Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief
http://pharmaceuticalintelligence.com
Streaming LIVE @Westin in Boston
12:30 pm – 1:00 pm
Bristol-Myers Squibb Ballroom
Bristol-Myers Squibb Ballroom
Fireside Chat: Andy Slavitt, Acting Administrator, CMS
Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC
- Pricing and cost of Cancer Care
- Programs that accomplished cost containment
- Funding to make a difference
- US vs Europe – HealthCare sector
- How CMS shapes by who is heading it
Andy Slavitt, Acting Administrator, CMS
- ACA is bringing better quality of life to Patients that did not have coverage before
- Affordability requires execution
- 140 Million Patients eligible to MediCare – will double enrolees in coming years
- MedicAid – many with Health challenges
- Goal to keep most in their own home vs nursing homes
- Pricing increase astronomically — there is difference in pricing from State to State
- Chronic disease: doubling down Primary Care to be reinvigorate
- Program for Oncologist – complete the Care for one Patient and for all
- Policy design, evolve, learn and change then continue
- HealthCare in CA vs TX is very different
- right infrastructure in place – models that communicate across all stackholders
- Transparent system is the most important thing
- Precision Medicine: CMS, NIH, NSF
- Value based model: rewards by desired outcome – Gov’t reimbursement by results
- Hospitals: Payment Primary Care Model vs Specialty model
1:00 pm – 1:30 pm
Bristol-Myers Squibb Ballroom
Bristol-Myers Squibb Ballroom
Fireside Chat: Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
Introduction by: Thomas Lynch, MD, CEO, Mass General Physician’s Organization
Moderator: Meg Tirrell, Biotech and Pharma Reporter, CNBC
- Development path for Optiva
- allocation of resources for game changers
- Partnerships
- alternative models for drug development
- Biomarkers
- Cure
Giovanni Caforio, MD, CEO, Bristol-Myers Squibb
- Collaboration Industry and Academia: Basic Science – Community based Oncology
- Innovation for the Patient who is the cental focus point
- Science is the leading factor – Follow Science
- Inflammation at tumor side — initiated clinical trials
- Combinations in immuno-therapy
- Drugs must be affordable, access to clinical trials – Priority
- Patients are there, that are not care for
- Methastatic melanoma – hope could have offered only by new drugs
- deep knowledge of Oncology and Immunology
- Oncology is a priority – commitment is across the entire portfolio
- Process to make decision of drug development the most promising are selected
- 3 approved and 8 in development – oncology drugs at BMS
- Partnerships need to be with Academic institutions, they do the basic research with BMS
- How Science correlate with development
- Strong scientific collaborations – to accelerate the process
- Pharm needs to work with Regulators and Hospitals – combine different mechanisms to price drugs
- combination need to be developed together to understand how to combine an dhow to price
- Education of MDs about the combination drug therapy
- Biomarkers: are very important
- Precision medicine (individuals) vs Oncology drugs (Population)
- Immuno-oncology – now it is the hope — if longevity is ten years it is in fact = Cure
Leave a Reply